Back to search

Article

Comparing efficacy and safety of Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Bayesian network meta-regression analyses

2023-07-13

Abstract excerpt

<h4>Background: </h4> Despite surgical and medical efforts in the upfront treatment, about 70% of OC patients have a disease relapse within 2–3 years after diagnosis. ROC is still an incurable condition; targeted agents as maintenance therapies have been shown to improve survival, but the most appropriate maintenance regimens are still controversial and opaque. <h4>Objective: </h4> This Bayesian network meta-regre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
93170f46-f856-5cff-bd73-60445384251d
DOI
10.21203/rs.3.rs-3150049/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparing efficacy and safety of Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Bayesian network meta-regression analysesDOI 10.21203/rs.3.rs-3150049/v1
Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled TrialsSemantic proximity
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.Semantic proximity
Exploratory Bayesian Synthesis of Targeted Agents Combined With Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer: A Network Meta-analysis of Single-Arm StudiesSemantic proximity
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United StatesSemantic proximity
Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity
A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapySemantic proximity
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisSemantic proximity
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy.Semantic proximity
Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)Semantic proximity
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerSemantic proximity
Select a neighboring publication to make it the new centre.